GATC Health Paper Quantifies AI-Driven Capital Efficiencies and Advances Human-Centered Drug Discovery
IRVINE, Calif., May 22, 2025 /PRNewswire/ -- GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine. The paper details how advancements such as GATC's Multiomics Advanced Technology™ (MAT) platform are reshaping pharmaceutical development by improving speed, cost, and accuracy while reducing reliance on animal testing through human-relevant AI models. Ultimately, these technologies provide practical solutions to the industry's key challenges and promise to deliver better, safer treatments—faster—to patients.
Highlights include:
Validated, Highly Accurate Predictions: GATC Health's MAT was validated by University of California, Irvine, with predictions of sensitivity at 86% and specificity at 91%.
Digital Twin Models: Models of human biological systems can test thousands of drug candidates in silico—achieving results 1,000x faster than conventional methods and at dramatically lower cost.
Reduction in Animal Testing: The platform simulates human biology, enabling accurate predictions without animal studies and supporting regulatory shifts like the FDA Modernization Act. AI-driven methods could replace animal testing for up to 38.4 million animals annually.
Public Health Impact: Accelerated drug development means faster access to new therapeutics, with the potential to save millions of years of human life.
"This paper underscores our commitment to scientific and ethical progress in drug discovery," said Jayson Uffens, Chief Technology Officer at GATC Health. "By improving capital efficiency and reducing animal testing, we aim to advance both innovation and responsibility in the industry."
Transforming Drug Development EconomicsTraditional drug development can cost up to $2.4 billion and take 12 years per drug. GATC's MAT platform streamlines discovery and preclinical phases, enabling companies to avoid costly investments in unlikely candidates and reinvest savings into further research. As noted in the paper, AI-driven preclinical assessments can cut animal use, increase human relevance, and reduce expenses by up to 90%. This streamlined process can shorten time to Investigational New Drug (IND) filing from over a decade to under two years.
Advancing Ethical, Cost-Effective SolutionsConventional animal models often fail to predict human outcomes and raise ethical issues. GATC's AI-driven approach reduces animal use by up to 70% per drug candidate, aligning with global moves toward non-animal testing. Virtual toxicology datasets and digital twins replace animal models with more accurate and humane alternatives.
Aligning with Regulatory TrendsThe paper details how AI technologies support evolving regulatory requirements, enabling faster, more precise, and ethically responsible drug development. GATC Health invites industry stakeholders to review the full paper and participate in the ongoing dialogue about the future of drug discovery. Visit GATC Health's Resources page to download the full paper.
About GATC HealthGATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company's validated and proprietary Multiomics Advanced Technology™ (MAT) simulates human biochemistry's billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and derisk drug pipelines by predicting efficacy, safety, and off-target effects.For more information, visit www.gatchealth.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/gatc-health-paper-quantifies-ai-driven-capital-efficiencies-and-advances-human-centered-drug-discovery-302462555.html
SOURCE GATC Health Corp
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
LONGi Ranks on the Bloomberg Tier 1 List
XI'AN, China, June 5, 2025 /PRNewswire/ -- On June 2nd, Bloomberg New Energy Finance (BNEF), a renowned global research institution, released its "Global PV Module Maker Tier 1 List" for Q2 2025. LONGi, leveraging its exceptional comprehensive strength, has secured a position on the highly anticipated Tier 1 (Level 1 PV Module Manufacturers) list. As one of the most credible industry rating systems in the global new energy sector, BNEF's " Global PV Module Maker Tier 1 List " is known for its rigorous evaluation criteria. The rating system takes bankability as its core consideration — namely, whether an enterprise's products can secure non-recourse debt financing from banks. Meanwhile, it requires manufacturers to physically own production facilities and sell products under their own brands, ensuring the professionalism and authority of the rating through qualification thresholds. The Tier 1 criteria are even more rigorous: The enterprise must have supplied modules for six different projects with its own brand and self-produced products in the past two years; These projects must have obtained non-recourse financing from six different (non-development) banks; The scale of the above transactions must exceed 10 MW. All the above conditions are indispensable, and failure to meet any one of them will result in removal from the list. It is worth noting that in Q2 2025, the transaction scale was increased from 5 MW to 10 MW for the first time, making the number of listed enterprises fewer than previous years. For this reason, the BloombergNEF Tier 1 list is often regarded as a fair, objective, and highly credible reference. It serves as an important basis for global PV project investment attraction, risk assessment by financial institutions, and market expansion by enterprises. As a leading global solar technology company, LONGi's ranking on the Tier 1 list not only demonstrates the continuous improvement of its brand credibility and the steady growth of its market competitiveness, but also represents the industry's high recognition of LONGi's comprehensive strength. LONGi has been ranked on the list multiple times. LONGi has always continued to strive for technological innovation and product engineering. Its high-efficiency and reliable Hi-MO series products are highly favored by the market, providing stable and efficient clean energy solutions for numerous global PV projects. In terms of operation and management, LONGi has always maintained a steady development strategy, demonstrating strong risk resistance and bankability, which has earned high trust from the global PV market and financial sector. With the global acceleration of the transition to clean energy, LONGi will continue to focus on technology leadership and join hands with the industry to march toward new heights. View original content to download multimedia: SOURCE LONGi Solar Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
13 minutes ago
- Yahoo
Rapid Weight Loss Without Proper Exercise and Nutrition Is Becoming Too Common
It's Time for Sustainable Habit Changes SAN DIEGO, June 5, 2025 /PRNewswire/ -- The emergence of GLP-1 medications in recent years has presented a promising option for many people who are struggling with weight management. With celebrity promotions and advertisements dominating the media landscape, there is a narrative that suggests weight loss should be as easy as a pharmacy visit. However, it's time to add more to this story. The GLP-1 (glucagon-like peptide-1) class of medications, including Ozempic, Wegovy, and many other brand names, has shown remarkable efficacy and effectiveness in promoting weight loss. By enhancing feelings of satiety and reducing hunger, these medications help individuals consume fewer calories and, consequently, lose weight. Even better, recent studies are showing that these anti-obesity medications may also reduce individuals' risks for heart attack and stroke and could help slow cognitive decline and protect against Alzheimer's disease. But what's missing from the feel-good news here is the necessity for people taking the medication to adopt new habits that will sustain healthier living. "GLP-1 medications seem to be a powerful anti-obesity tool, but they also have an impact on muscle mass and nutrient intake," said American Specialty Health Senior Vice President of Rehabilitation Services and Digital Self-Care Solutions Jaynie Bjornaraa, PhD, MPH, PT. "So, while fitting into that swimsuit may be the goal, people should also consider how to stay fit enough to carry their beach bags and umbrellas to the shore. Especially, if they're going it alone." According to Dr. Bjornaraa, the combination of GLP-1 medications and attention to fitness and nutrition can create a synergistic effect, leading to more significant and sustainable weight loss outcomes. "Research has shown that individuals who receive comprehensive support, including behavioral interventions, are more likely to achieve and maintain their weight loss goals compared to those who rely solely on medications," Dr. Bjornaraa said. What does this look like? "In the fight against obesity, success can be greatly amplified when combining a fitness and nutrition regimen with personalized health coaching," said Dr. Bjornaraa. "Health coaches provide invaluable support, guidance, and accountability to individuals, helping them navigate the complexities of lifestyle changes and maintain long-term success." Dr. Bjornaraa points out one of the key benefits of health coaching is the focus on behavioral change. Coaches collaborate with clients to identify and overcome barriers to weight loss, such as emotional eating, stress, and lack of "stick-to-it-iveness." By addressing underlying issues, health coaches empower individuals to adopt healthier habits and sustain their weight loss efforts. Health coaches offer tailored advice and strategies based on the unique needs and circumstances of individuals. They help people set realistic and achievable goals, develop healthy eating habits, and make informed exercise choices. This personalized approach ensures that individuals receive the support they need to make lasting changes. "Long-term weight loss maintenance is often the most challenging aspect of the weight loss journey," said Dr. Bjornaraa. "Health coaching provides the ongoing support necessary to help individuals stay on track and avoid regaining lost weight. This continuous engagement ensures that the positive effects of GLP-1 medications are sustained over time. For those embarking on their GLP-1 journeys, incorporating health coaching can be an essential component of success." Overall, adopting a healthier lifestyle by establishing a fitness routine that includes strength training, supplemented by good nutrition, which can be aided by health coaching, complements the effects of GLP-1 medications according to Dr. Bjornaraa. "You could say it pairs well," Dr. Bjornaraa said. "And by fostering a comprehensive approach to weight management, individuals will be better equipped to make lasting changes that support their overall health and well-being." So, it's clear how this approach can benefit individuals on a weight loss journey, but what does this mean for health plans and others in the healthcare industry? "Well, given the greater effectiveness of this approach," said Dr. Bjornaraa, "health plans could consider providing personalized guidance for exercise and nutrition as well as behavioral support to enhance the benefits of these medications and the long-term weight loss success for their members. "This would provide their members with a healthier path to achieve their weight loss goals while possibly helping to reduce obesity, heart attack, stroke, and Alzheimer's disease amongst their member population," she added. Overall, she says, this leads to a healthier America, which we should all be striving to attain. About American Specialty Health American Specialty Health Incorporated (ASH) is one of the nation's premier independent and privately owned specialty health organizations offering technology-enabled services for benefits management and administrative services for health plans, and partners with employers, associations, and others. ASH currently covers 62+ million eligible members nationwide. With offices in California and Indiana, ASH has more than 1,700 employees. For more information about ASH, visit follow us on LinkedIn and Facebook; or call 800-848-3555. Media Contacts:Jack ChirrickAmerican Specialty Health Inc.(619) 557-2361jackc@ View original content to download multimedia: SOURCE American Specialty Health Incorporated Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
39 minutes ago
- Yahoo
Yiren Digital to Report First Quarter 2025 Financial Results on June 12, 2025
BEIJING, June 5, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital"), an AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia, announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2025 before U.S. market opens on Thursday, June 12, 2025. Yiren Digital's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on June 12, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on June 12, 2025). Participants who wish to join the call should register online in advance of the conference at: Once registration is completed, participants will receive the dial-in details for the conference call. Additionally, a live and archived webcast of the conference call will be available at About Yiren Digital Yiren Digital Ltd. is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in Asia. Our mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. We support clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses. View original content: SOURCE Yiren Digital Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
